12:00 PM: Pick up your badge at the Welcome Desk. Lunch & Learn Workshops, Networking.

1:00 PM: Opening Conversations with Boston/Paris Officials (TBC) / Summit Co-founders

1:15 PM: Business Perspectives Conversation: Snapshot of the US Economy relevant to Biotechs at mid-year point

Mac Martirossian, CPA, MThree Advisory, Atlanta GA

1:30 PM: MASTER CLASS: State-of-the-Art in R&D 2023: A Trans-Atlantic Perspective

Claude Bertrand, PhD,  Executive Vice President & Chief Scientific Officer, Servier

Novartis, Roche, Pfizer, AstraZeneca, Ipsen, Servier

Master Class Moderated by Dr Shahin Gharakhanian, Summit Program Chair

2:30 PM: <ART & SCIENCE OF ENGAGING BOSTON ACADEMIC CENTERS>

Professor Reza DANA, Harvard Medical School  

Shared Experience & Viewpoints of a Boston Academic Leader

Harvard Medical School,  Chair in Ophthalmology, Vice Chairman for Academic Programs Director, Harvard-Vision Clinical Scientist Development Program, Co-Director, Cornea Center of Excellence, Massachusetts Eye and Ear Infirmary: Director of Cornea Service Associate Chief for Academic Programs, Senior Scientist, Director of the Laboratory of Immunology

Dr Cecile LA CAMUS, SANOFI, Boston MA.

Shared Experience & Viewpoints of a Bio-Pharmaceutical Executive

Head of Global Medical Affairs (Hemophilia), SANOFI. Formerly, Head of US Medical Affairs & Organizational Excellence Global Medical Affairs at VERTEX Pharmaceuticals

Dr Vanessa EL HARRAR [Session Moderator], PPD Biotech, USA

Shared Experience & Viewpoints of a Global CRO Executive

Vice-President Vaccine Business Strategy PPD Biotech. PPD Biotech was Moderna’s CRO. This CRO has received numerous awards for its achievements.  Formely, Director at Office of the Director, National Institutes of Health, MD, USA

Program Committee Discussant: Dr Abderrahim Lachgar,CEO Par’Immune, Lille,&  Board of Directors, Apmonia, Reims,  France

3:30 PM: SUMMIT CORE SESSION <STATE-of-the-ART 2023:

ARTIFICIAL INTELLIGENCE APPLIED TO BIO-PHARMA R&D>

Dr Mark CHANG, Boston University, Boston USA

Overview of the state of our knowledge in artificial intelligence in 2023

Author, Textbook of <Artificial Intelligence in Drug Development, Precision Medicine and Healthcare>. Founder, ADInception. co-founder of the International Society for Biopharmaceutical Statistics

Professor Bradley PENTELUTE, Massachusetts Institute of Technology, Cambridge MA.

Applications of Artificial Intelligence in Biotechnology R&D

Department of Chemistry, MIT. His research program lies at the intersection of chemistry and biology and develops bioconjugation strategies, cytosolic delivery platforms, and rapid flow synthesis technologies to optimize the production, achieve site-specific modification, enhance stability, and modulate function of a variety of bioactive agents

Dr Jonathan SIDI, SAGE Therapeutics. Cambridge MA. Director of Modeling and Simulation

Applications of Artificial Intelligence in a Company with Large Clinical Development Programs and Commercialized Medicines

Dr Sidi currently works CNS disease progression modeling, Go/No Go decision making criteria, Dose / Exposure Response modeling and clinical trial simulations

SESSION MODERATOR: TBC

Program Committee Discussant: Hector Rosado, MBA, TAKEDA Pharmaceuticals

4:45 PM:  THE FAMOUS BOSTON SUMMIT PITCH SESSION

This ever popular session will feature 5~8 selected, award winning start-ups who will pitch to a senior and highly expert panel composed of Pharma Business Development, Biotech executives and Investors (Angel, VC). Companies who have received distinctions by recognized professional bodies will pitch for a gold medal first place which will be accompanied by business benefits.

JURY MEMBERS (alphabetically ordered):

James CAROLL, MBA, Chief Executive Leadership, Early Financing, Founder & Managing Partner. Boston Life Science Investors [Est. 2013]

Malini CHATTERJI, PhD, Managing Director, Blueprint Life Science Group, New York, NY, USA

Leslie P. COUSENS, PhD, Senior Director, Search & Evaluation, Respiratory & Immunology ASTRAZENECA, BioPharmaceuticals R&D | Business Development, Licensing & Strategy

Cecile LE CAMUS, MD, MBA, Global Head of Hemophilia for RBD: Rare Blood Disorders, Medical Affairs Group, SANOFI, BOSTON MA, USA

Eric EVANS, MBA, Executive Committee, Mass Medical Angels (M2A), Boston MA, USA

Retsina MYER, PhD, Head of Corporate Strategy, DELIX Therapeutics, Cambridge MA, USA

[Additional Major Pharmaceutical Company, TBC]